On January 31, 2024, ZHB103 Injection, a new drug in Class 1 of therapeutic biologics originally developed by ZONHONBIO, which has completely independent intellectual property rights at home and abroad, was granted the “Notice of Approval for Clinical Trial of Drugs” by the NMPA. The approved indication is transient ischemic attack or mild ischemic stroke.